NEW YORK (GenomeWeb News) - The National Institutes of Health is making a prostate cancer-related genotyping technology available for either exclusive or non-exclusive licensing.
 
The National Cancer Institute’s Medical Oncology Branch is seeking interested research collaborators to develop, evaluate, or commercialize the use of this technology, which is used to predict survival prognoses for prostate cancer patients.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.